Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

10.68 -0.41 (-3.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
What Is Going on With Intellia Therapeutics (NTLA) Stock Today? ↗
Intellia Therapeutics (NTLA) stock is on the move Friday after releasing positive clinical trial data for two of its drugs. 
Via InvestorPlace
News headline image
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Expert Ratings for Intellia Therapeutics ↗
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Expert Ratings for Intellia Therapeutics ↗
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
News headline image
Recap: Intellia Therapeutics Q2 Earnings ↗
  Intellia Therapeutics (NASDAQ:NTLA) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate ↗
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE).... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis ↗
 
Via Benzinga
News headline image
Where Intellia Therapeutics Stands With Analysts ↗
Over the past 3 months, 5 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Macy's, Palo Alto Networks And Other Big Gainers From Tuesday ↗
U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher ↗
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
News headline image
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
7 Stock Price Predictions That Are Actually Worth Listening To ↗
Investors may take advantage of analyst stock price predictions beyond the recent share price to discover promising investments. 
Via InvestorPlace
News headline image
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
News headline image
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug ↗
The company will compete with Pfizer, which already has an approved drug. 
Via Investor's Business Daily
News headline image
Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday ↗
  AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days. 
Via Benzinga
News headline image
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned ↗
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients. 
Via Investor's Business Daily
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
News headline image
7 Cathie Wood Stocks Trading at a Discount Right Now ↗
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
The 3 Leaders of the Gene Editing Revolution ↗
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
News headline image
7 Moonshot Investments Upending a $10 Trillion Industry ↗
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
News headline image
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names ↗
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
News headline image
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying ↗
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.